Use of compound or composition comprising NLRP1 inflammasome activation inhibitor for treatment of human airway inflammation
The present invention relates to a method of preventing or treating airway inflammation and/or related complications triggered by enterovirus 3C protease activated NLRP1 by using a compound or composition comprising an inhibitor of NLRP1 inflammasome activation. In one embodiment, the enterovirus 3C...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
30.12.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a method of preventing or treating airway inflammation and/or related complications triggered by enterovirus 3C protease activated NLRP1 by using a compound or composition comprising an inhibitor of NLRP1 inflammasome activation. In one embodiment, the enterovirus 3C protease is from a viral species selected from the group consisting of human enterovirus A (HEV-A), human enterovirus B (HEV-B), human enterovirus C (HEV-C), human enterovirus D (HEV-D), human rhinovirus A (HRV-A), human rhinovirus B (HRV-B), and human rhinovirus C (HRV-C). In some embodiments, the compound is selected from the group consisting of MLN 4924, TAS4464, ZM223, MG132, and bortezomib.
本发明涉及一种通过使用包含NLRP1炎性体激活抑制剂的化合物或组合物来预防或治疗由肠道病毒3C蛋白酶激活的NLRP1触发的气道炎症和/或相关并发症的方法。在一个实施方案中,所述肠道病毒3C蛋白酶来自选自以下的病毒物种:人肠道病毒A(HEV-A)、人肠道病毒B(HEV-B)、人肠道病毒C(HEV-C)、人肠道病毒D(HEV-D)、人鼻病毒A(HRV-A)、人鼻病毒B(HRV-B)和人鼻病毒C(HRV-C)。在一些实施方案中,所述化合物选自MLN4924、TAS4464、ZM223、MG132和硼替佐米。 |
---|---|
Bibliography: | Application Number: CN202180034911 |